The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

BioMarin to Host Second Quarter 2010 Financial Results Conference Call and Webcast on Monday, August 2 at 5:00 p.m. ET

Tuesday, July 06, 2010

BioMarin to Host Second Quarter 2010 Financial Results Conference Call and Webcast on Monday, August 2 at 5:00 p.m. ET09:00 EDT Tuesday, July 06, 2010NOVATO, Calif., July 6 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, August 2, at 5:00 p.m. ET to discuss second quarter 2010 financial results.U.S. / Canada Dial-in Number: �800.573.4840International Dial-in Number: �617.224.4326Participant Code: 78258415Replay Dial-in Number: 888.286.8010Replay International Dial-in Number: 617.801.6888Replay Code: 76507562Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme� (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme� (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan� (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse? (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA; PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU and BMN 195, which is currently in Phase I clinical development for the treatment of Duchenne Muscular Dystrophy. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.BioMarin�, Naglazyme� and Kuvan� are registered trademarks of BioMarin Pharmaceutical Inc.Firdapse? is a trademark of BioMarin Huxley Ltd.Aldurazyme� is a registered trademark of BioMarin/Genzyme LLC.Contacts:InvestorsMedia Eugenia ShenSusan BergBioMarin Pharmaceutical Inc.BioMarin Pharmaceutical Inc.(415) 506-6570(415) 506-6594SOURCE BioMarin Pharmaceutical Inc.For further information: Investors, Eugenia Shen, +1-415-506-6570, or Media, Susan Berg, +1-415-506-6594, both of BioMarin Pharmaceutical Inc.